Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors.

Sylvie Picard, Srinivasan Parthasarathy, Joachim Fruebis, Joseph L. WitztumProceedings of the National Academy of Sciences 1992 · DOI

TL;DR

This paper investigates aminoguanidine's potential to inhibit the oxidative modification of LDL, a key process in atherosclerosis. They found that aminoguanidine effectively prevents LDL from becoming a ligand for scavenger receptors on macrophages by trapping reactive aldehydes, suggesting a dual benefit in combating diabetes complications and atherosclerosis.

What Problem Does This Paper Address?

Atherosclerosis, a major cause of heart disease, is strongly linked to the oxidative modification of low-density lipoprotein (LDL). When LDL is oxidized, its apolipoprotein B (apo B) undergoes chemical changes, particularly the derivatization of lysine residues by reactive aldehydes. This modified LDL is no longer recognized by normal cellular LDL receptors but is instead avidly taken up by scavenger receptors on macrophages. This process contributes to the formation of foam cells, a hallmark of atherosclerotic plaques.

The paper draws an analogy to advanced glycosylation end products (AGEs) that form in chronic hyperglycemia (like in diabetes). AGEs also involve modifications of lysine residues and lead to protein crosslinking, contributing to diabetic complications. Aminoguanidine is known to inhibit AGE formation by binding to early glycosylation products. The researchers hypothesized that aminoguanidine might similarly inhibit LDL oxidation by binding to the reactive aldehydes produced during lipid peroxidation, thereby preventing their conjugation to apo B.

Methods

The researchers employed several key experimental techniques:

  • LDL Oxidation: Unlabeled and radioiodinated LDL (¹²⁵I-LDL) were oxidized using two methods: incubation with cultured rabbit aortic endothelial cells (EC) or incubation with copper ions (Cu²⁺). These oxidations were performed in the presence or absence of varying concentrations of aminoguanidine.
  • Lipid Peroxidation Measurement:
    • TBARS Assay: Thiobarbituric acid-reactive substances (TBARS) were measured to quantify lipid peroxidation products, expressed as nmol equivalents of malondialdehyde (MDA).
  • Conjugated Diene Formation: The absorbance at 234 nm was monitored over time to track the formation of conjugated dienes, an early indicator of lipid peroxidation.
  • Protein Modification Assessment:
    • Electrophoretic Mobility: Changes in the electrophoretic mobility of LDL on agarose gels were used to assess the negative charge increase on apo B due to modifications.
  • Fluorescence Spectroscopy: Oxidized LDL exhibits characteristic fluorescence due to Schiff base adducts formed between reactive aldehydes and lysine residues. This fluorescence was measured to quantify protein modification.
  • MDA-LDL Modification: LDL was deliberately modified with exogenous MDA in the presence or absence of aminoguanidine. The percentage of lysine residues modified by MDA was determined using the trinitrobenzenesulfonate assay.
  • Macrophage Uptake and Degradation: ¹²⁵I-LDL, after oxidation, was incubated with mouse peritoneal macrophages. The rate of LDL degradation was measured by quantifying the trichloroacetic acid-soluble radioactivity in the medium and cell-associated radioactivity.
  • Antioxidant Activity Assay: Aminoguanidine's potential to act as a direct antioxidant was tested using a xanthine/xanthine oxidase system to generate superoxide anions, monitoring the reduction of cytochrome c.

Datasets

Not discussed in the paper. The experiments utilized isolated LDL, cultured endothelial cells, and primary macrophages from mice.

Key Insights and Ideas

  • Aminoguanidine as an Aldehyde Scavenger: The central idea is that aminoguanidine doesn't necessarily act as a traditional antioxidant by directly neutralizing free radicals. Instead, it preferentially binds to reactive aldehydes (like MDA) that are byproducts of lipid peroxidation. This "aldehyde trapping" prevents these reactive species from modifying apo B.
  • Dual Benefit Hypothesis: The paper proposes that aminoguanidine could be beneficial in two ways: by inhibiting AGE formation (relevant to diabetes complications) and by inhibiting LDL oxidation (relevant to atherosclerosis). This dual action makes it a potentially powerful therapeutic agent.
  • Selective Inhibition: Aminoguanidine appears to inhibit the modification of apo B that leads to scavenger receptor recognition, even if overall lipid peroxidation (measured by diene conjugation) proceeds to a similar plateau. This suggests it specifically targets the formation of the "ligand" for macrophages.
  • Concentration-Dependent Effects: The study highlights dose-dependent effects of aminoguanidine, with significant inhibition of LDL modification and macrophage uptake observed at concentrations of 5-10 mM.

Key Results

  • Aminoguanidine significantly inhibited the oxidative modification of LDL, as evidenced by reduced apo B lysine modification (measured by fluorescence) and decreased electrophoretic mobility.
  • This inhibition of LDL modification led to a dose-dependent decrease in the subsequent uptake and degradation of oxidized LDL by macrophages. At 5 mM aminoguanidine, macrophage degradation was reduced by up to 60%.
  • Aminoguanidine prevented MDA from derivatizing lysine residues on apo B.
  • While aminoguanidine at higher concentrations (≥5 mM) prolonged the lag phase of conjugated diene formation, it did not significantly affect the final plateau level of lipid peroxidation, suggesting it primarily inhibits the rate of propagation rather than the overall extent.
  • Aminoguanidine did not demonstrate direct antioxidant activity in a xanthine/xanthine oxidase assay.

Limitations and Future Work

  • In Vitro vs. In Vivo: The study was conducted in vitro. While promising, the efficacy and safety of aminoguanidine in preventing atherosclerosis in vivo need to be confirmed.
  • Tissue Penetration: Aminoguanidine is a relatively hydrophilic compound. The authors suggest that more hydrophobic derivatives might achieve better penetration into the hydrophobic core of LDL and be more effective at lower concentrations.
  • Mechanism of Antioxidant Effect: While aminoguanidine didn't act as a direct radical scavenger in the tested system, its ability to delay conjugated diene formation suggests it might act as an antioxidant by inhibiting propagation, possibly by reacting with peroxy radicals. Further investigation into this mechanism is warranted.
  • Clinical Relevance of Concentrations: The paper notes that plasma levels of about 13 mM have been reported in rodents after oral feeding, suggesting the tested concentrations might be achievable in vivo. However, clinical studies in humans are still underway.
  • Future Directions: The authors propose that it would be important to determine if aminoguanidine can inhibit atherosclerosis in nondiabetic animal models and prevent diabetic complications and atherosclerosis in diabetic animals. They also suggest that separating the effects of AGE formation from LDL oxidation inhibition could be achieved by using LDL oxidized in the presence of aminoguanidine.

Summary updated

Abstract

Aminoguanidine decreases the formation of advanced glycosylation end products that occurs during chronic hyperglycemia. Presumably this occurs because early glycosylation products preferentially bind to aminoguanidine rather than to lysine groups of adjacent proteins. Because oxidative modification of low density lipoprotein (LDL) also involves derivatization of lysine residues of apolipoprotein (apo) B by reactive aldehydes formed during the decomposition of oxidized fatty acids, we postulated that aminoguanidine might also inhibit the oxidatively induced modification of LDL protein. To test this hypothesis we oxidized LDL by incubation with Cu2+ or with endothelial cells in the absence or presence of aminoguanidine. Aminoguanidine prevented apo B lysine modification, as measured by fluorescence spectroscopy, and inhibited in a dose-dependent manner the oxidatively induced increase in subsequent macrophage uptake. At concentrations that inhibited apo B modification (5-10 mM), aminoguanidine increased the lag time in diene conjugation but did not affect the plateau value reached. These data indicate that aminoguanidine inhibits oxidative modification of LDL protein in large part by binding reactive aldehydes formed during lipid peroxidation and preventing their subsequent conjugation to apo B. Thus, aminoguanidine (and related compounds) may be of dual benefit in inhibiting atherosclerosis, both by inhibiting formation of advanced glycosylation end products and by inhibiting the modification of LDL apo B that makes it a ligand for scavenger receptors.
BibTeX
@inproceedings{picard1992aminoguanidine,
  author = {Sylvie Picard and Srinivasan Parthasarathy and Joachim Fruebis and Joseph L. Witztum},
  title = {{Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors.}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {1992},
  doi = {10.1073/pnas.89.15.6876},
}
Figure